BAN2401 Phase 3 Clinical Trial Starting April 2019First Choice Neurology is seeking patients for BAN2401 phase 3 dementia clinical trial.
By: First Choice Neurology BAN2401 is a humanized monoclonal antibody for Alzheimer's disease that targets the protofibrils of beta-amyloid before they aggregate into amyloid plaques. BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai and Biogen are offering patients to participate in the phase 3 study starting in April 2019. Dr. Victor Faradji of First Choice Neurology is one of the Principal Investigators of the BAN2401 clinical trial. Contact Nicole Good at 954-258-7389 to be considered in the BAN2401 phase 3 clinical trial for dementia. Or email Nicole at NGoood@vintrials.com About Victor Faradji, MD Victor Faradji, MD is Board Certified by the American Board of Psychiatry and Neurology. He practices general adult and adolescent neurology with special interest in electromyography (EMG), neuromuscular and spinal disorders, migraine, vertigo, and Dementia. Dr. Faradji has participated in many scientific research studies including diabetic neuropathy and the IDEAS study for Alzheimer's disease. About First Choice Neurology First Choice Neurology services patients with a variety of neurological conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, neuromuscular disorders, Parkinson's disease, sleep disorders, strokes, and more. They have several locations throughout Florida. For more information about First Choice Neurology and the BAN2401 clinical trial, visit their website at https://www.fcneurology.net End
Account Email Address Account Phone Number Disclaimer Report Abuse
|